Founding Partners Of NetraPharma

Greg Bailey

CEO of Juvenescence Limited

Dr Bailey is the CEO of Juvenescence Limited a company develops therapeutics so people can live longer healthy. Juvenescence develops drugs, IP protected consumer products and other therapeutic

modalities to slow aging and increase a healthy lifespan. The company uses AI to augment its drug discovery and drug development programs in partnership with Insilico Medicine. Dr Bailey has been founding and financing companies since 1995 these companies have traded on

NASDAQ, AIM, AMEX and the NYSE, reaching over $18 billion in market capitalization. These companies include Ascent Health Care that was sold to Stryker for $525 million and Medivation

Inc., (MDVN: NASDAQ) which was acquired by Pfizer in September 2016 for $14.3 billion. Gregory Bailey currently sits on the board of directors of 3 public companies Portage Biotech, Inc. (PTGEF:OTC), and SalvaRx PLC., (SALV.L:AIM); and Biohaven Pharmaceuticals, Inc., (BHVN:NYSE). SalvaRx is an immuno-oncology company which went public in February 2016.

Portage was the major shareholder in Biohaven investing $7million beginning in January 2014 until a dividend of $200 million of Biohaven shares to its shareholders. Dr Bailey remains a major

shareholder of Biohaven which went public in May 2017 and has a market cap of a little over a billion dollars.

Dr Bailey received his medical doctorate from University of Western Ontario.

Alexander Pickett

COO, Juvenescence Limited

Alexander Pickett is the Chief Operating Officer at Juvenescence Limited, a drug development company focused on aging and longevity.  Alexander is also a Principal at Mediqventures, a multi-family investment partnership and merchant bank.  While at Mediqventures, he led investments into Causeway Therapeutics Ltd and Sentien Biotechnologies, Inc., supported existing investments at Portage Biotech Inc. and Biohaven Pharma, and helped found SalvaRx Limited, a cancer-immunotherapy focused drug development company.

Prior to joining Mediqventures, he was an Associate at Flatley Venture Capital, a cystic fibrosis focused investment arm of a family office, where he was responsible for investment analysis and scientific due diligence. While there, he also supported Flatley Discovery Lab’s business development efforts.  Alexander co-founded Real Life Sciences, a start-up focused on using software-based patient-engagement solutions in order to improve patient recruitment to clinical trials.

Prior to joining Flatley Venture Capital, Alexander graduated from Harvard College with an A.B. in Molecular and Cellular Biology, where he was a Microbial Studies Initiative Undergraduate Fellow and an International Genetically Engineered Machines Competition Team Member.

Dr. Doogan

Co-founder Juvenescence

Dr. Doogan is a co-founder of the aging research company Juvenescence. He is co-founder and Chair of Biohaven a clinical stage biotechnology company (BHVN: NYSE). Dr. Doogan has served as the Chief Executive Officer and director of Portage Biotech, Inc. (PTGEF: OTCBB) since June 2013, a director of Portage Pharmaceuticals Limited since July 2013, and a director of Sosei Group Corporation since June 2007. Dr. Doogan has over 30 years of industry experience in both major pharma and biotech. He was the Senior Vice-President and Head of Worldwide Development at Pfizer. He has held a number of executive positions in Pfizer in the US, the UK and Japan. Since leaving Pfizer in 2007, he has been engaged in executive roles in small pharma. Dr. Doogan was chief medical officer and acting CEO of Amarin (AMRN: NASDAQ). Dr. Doogan holds a number of board appointments, principally in pharma companies, and has also held professorships at Harvard School of Public Health, Glasgow University Medical School and Kitasato University (Tokyo) and is Visiting Professor in Psychiatry at the University of Cork. Dr. Doogan received his medical degree from Glasgow University in 1975. He is a Fellow of the Royal College of Physicians and the Faculty of Pharmaceutical Medicine and holds a Doctorate of Science at the University of Kent in the UK.

(PTGEF:OTC), and SalvaRx PLC., (SALV.L:AIM); and Biohaven Pharmaceuticals, Inc.,

(BHVN:NYSE). SalvaRx is an immuno-oncology company which went public in February 2016.

Portage was the major shareholder in Biohaven investing $7million beginning in January 2014 until a

dividend of $200 million of Biohaven shares to its shareholders. Dr Bailey remains a major

shareholder of Biohaven which went public in May 2017 and has a market cap of a little over a

billion dollars.

Dr Bailey received his medical doctorate from University of Western Ontario.